Phase IThyroid Analog
Compound 61422
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061422
Risk Class
MODERATE
Last Audit
Feb 1, 2108
Research Abstract
Thyroid Analog candidate engineered for endocrine support initiatives with automated dossier coverage.
Compound 61422 is a thyroid analog asset inside thyroid analog innovation track initiatives, optimized for endocrine support and performance longevity.
The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061422 with updates logged 2108-02-01.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Endocrine supportPerformance longevity
Nomenclature
CX-61422Thyroid Analog Program 61422
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061422
- [2] Operations Pulse • Thyroid Analog innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61422